Evidence review · from the 250-topic plan
The semaglutide switch guide: moving to it, moving from it, without losing a week
Molecule switches are routine medicine with no official conversion chart: there's no published crosswalk between semaglutide's ladder and tirzepatide's, so clinicians map by judgment — typically landing a switcher at a middle rung of the new drug rather than its floor or ceiling, then adjusting by response. The mechanics are friendlier than people fear (no washout needed; swap at the next scheduled weekly dose; respect the 72-hour floor), the expectations should reset to the head-to-head's numbers, and the money runs $240/year between the audited flats in either direction. What actually goes wrong in switches is programs, not pharmacology — so the last section is the logistics interrogation.
The four reasons people switch
To semaglutide: cost (the $119 audited floor is the field's lowest all-in) and tolerability (some guts simply prefer the single agonist — individual variation is real and unpredictable). To tirzepatide: plateau at maximum tolerated semaglutide with the head-to-head's ~6.5-point average gap as the argument, or a from-the-start efficacy priority. All four are legitimate; all four are clinician conversations this page arms rather than replaces.
Switching to semaglutide, mapped
No crosswalk exists, so practice fills the gap: a patient established on mid-or-higher tirzepatide typically enters semaglutide at a middle rung (commonly the 0.5–1.0 mg zone, per clinician judgment) rather than restarting at 0.25 — the introduction dose exists for GLP-1-naïve guts, and yours isn't — then climbs toward 2.4 as tolerated. Expectations reset honestly: STEP-class averages run ~14.9%, so a switcher chasing savings should expect maintenance-or-modest-change, not a new descent. The prize is arithmetic: the audited sema year runs $1,428, $240 under the tirzepatide flat, with tier-market gaps far wider. The audited semaglutide floor ↗
Switching to tirzepatide, mapped
Same logic mirrored: an established 2.4 mg semaglutide patient typically enters tirzepatide at 2.5 or 5 mg by clinician judgment — often 2.5 briefly for GIP-introduction courtesy, climbing briskly as tolerated, since the incretin experience transfers even though the second receptor is new. Expectations reset upward but honestly: SURMOUNT-5's ~20.2% average was measured from treatment-naïve baselines, so a plateaued switcher should expect renewed movement, not the full headline. The cost runs the $240 the other way — the question is whether the average gap is worth twenty dollars a month, and for most budgets that clear it, the trial answers yes.
The mechanics, demystified
No washout: take the new molecule at the next scheduled weekly slot — overlapping tails are expected and fine; what's forbidden is two GLP-1 products concurrently as a regimen. The 72-hour floor between any two doses still governs. Side effects may reprise briefly — a new receptor profile can bring week-one echoes; the steady-state math says give the new dose its month before judging. Document the handoff: current molecule, dose, duration, in writing — the one artifact that makes any receiving clinician's mapping clean.
The program logistics — where switches actually break
Pharmacology forgives; billing departments don't always. Before switching, get written answers: "Does a molecule switch require a new plan, new fees, or a new commitment clock?" "Does my rate change?" "Is there a gap between last shipment of A and first of B?" Tiered and commitment programs frequently treat a switch as a fresh sale — new door price, restarted term — while the flat benchmark's published answer is that the plan simply re-prices to the other molecule's flat ($139↔$119) with the same terms. A switch should cost a conversation, not a re-enrollment; any program where it costs more has told you its architecture.
FAQ
Is there an official semaglutide-to-tirzepatide dose conversion?
No published crosswalk exists; clinicians map by judgment — typically entering the new molecule at a middle rung (or 2.5–5 mg for tirzepatide) and adjusting by response.
Do I need a washout between GLP-1 medications?
No — switch at the next scheduled weekly dose, keep 72+ hours between doses, and never run two GLP-1 products as a concurrent regimen.
Will I lose progress when I switch?
Levels overlap through the transition and clinician mapping preserves continuity; expectations should reset to the new molecule's trial averages rather than assuming loss or windfall.
What should I ask my program before switching molecules?
In writing: whether the switch triggers new fees, a new commitment clock, a rate change, or a shipment gap — the answers reveal the program's architecture.
Sources
- Zepbound and Wegovy prescribing information — initiation dosing, 72-hour language, single-GLP-1 rule.
- SURMOUNT-5 head-to-head; STEP and SURMOUNT programs for expectation baselines.
- Clinical practice literature on incretin switching; audited pricing — the open dataset, 2026-08-14.